Sunday, November 12, 2023
- 9:00AM-11:00AM
-
Abstract Number: 0055
Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses
(0040–0064) Innate Immunity Poster- 9:00AM-11:00AM
-
Abstract Number: 0558
Elevated Serum Levels of S100A8/A9 Discriminate Systemic Lupus Erythematosus Patients with Cognitive Impairment from Patients Without Impairment
(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I- 9:00AM-11:00AM
-
Abstract Number: 0576
Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers
(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I- 9:00AM-11:00AM
-
Abstract Number: 0039
Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis
(0013–0039.5) Genetics, Genomics & Proteomics Poster- 9:00AM-11:00AM
-
Abstract Number: 0126
Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population
(0117–0144) Epidemiology & Public Health Poster I- 9:00AM-11:00AM
-
Abstract Number: 0365
Establishing a Multidisciplinary Registry for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: Insights into Patient Outcomes and Management Challenges
(0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA- 9:00AM-11:00AM
-
Abstract Number: 0652
Ethnic Variations in Systemic Sclerosis Associated Interstitial Lung Disease
(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research- 9:00AM-11:00AM
-
Abstract Number: 0639
Evaluating Esophageal Dysmotility by Scintigraphy in Systemic Sclerosis: Subsets and Phenotypes
(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research- 9:00AM-11:00AM
-
Abstract Number: 0658
Evaluating the Associations Between Autonomic Dysfunction, Clinical Phenotype and Gastrointestinal Transit in Patients with Systemic Sclerosis
(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research- 9:00AM-11:00AM
-
Abstract Number: 0555
Evaluation and Management of the “False Positive” ANA and Undifferentiated Connective Tissue Disease Amongst Rheumatologists
(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I- 9:00AM-11:00AM
-
Abstract Number: 0582
Evaluation of Anifrolumab Treatment Responses by the Short Form 36 Health Survey Version 2 in SLE: A Post Hoc Analysis of the Placebo-Controlled Phase 3 Long-Term Extension Trial
(0582–0608) SLE – Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 0174
Evaluation of Healthcare Utilization in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
(0155–0175) Health Services Research Poster I- 9:00AM-11:00AM
-
Abstract Number: 0084
Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function
(0066–0095) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 0003
Expanded Extrafollicular B Cells Were Improved by RTX in IgG4-related Disease